HIV Infections Clinical Trial
Official title:
NIMH Project Accept: A Phase III Randomized Controlled Trial of Community Mobilization, Mobile Testing, Same-Day Results, and Post-Test Support for HIV in Sub-Saharan Africa and Thailand
This study will evaluate the effectiveness of a combination of clinic- and community-based voluntary counseling and testing programs in preventing HIV in African and Thai communities.
| Status | Completed |
| Enrollment | 192814 |
| Est. completion date | September 2011 |
| Est. primary completion date | September 2011 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 16 Years and older |
| Eligibility |
Inclusion Criteria: Baseline Assessment: Persons may be included in the baseline behavioral assessment if they meet all of the following criteria: - Reside in a community selected for the study - Are randomly selected and invited to participate from households that are themselves randomly selected and invited to participate - Aged 18-32 years - Has lived in the community at least 4 months in the past year - Sleeps regularly in their household at least 2 nights per week - Able and willing to provide verbal informed consent Qualitative Cohort: Persons may be included in the qualitative cohort if they meet all of the following criteria: - Participated in the baseline behavioral assessment - Aged 18-32 years at enrollment - Have not been away from the community for more than two months at a time in the last two years - Able and willing to provide written informed consent Intervention: Persons may access community-based counseling and testing (in CBVCT communities) through the study if they meet all of the following criteria: - >16 years of age - Able and willing to provide verbal informed consent Persons may access post-test support through the study if they meet all of the following criteria: - >16 years of age - Able and willing to provide verbal informed consent - Proof of having been tested for HIV at a Project Accept CBVCT venue, irrespective of test result Control: Persons may access standard clinic-based counseling and testing (in both SVCT and CBVCT communities) through the study if they meet all of the following criteria: - >16 years of age - Able and willing to provide verbal informed consent Post-Intervention Assessment: Persons may be included in the post-intervention assessment if they meet all of the following criteria: - Reside in a community selected for the study - Are randomly selected to be offered to participate from households that are themselves randomly selected to be offered to participate - Aged 18-32 years - Has lived in the community at least 4 months in the past year - Sleeps regularly in their household at least 2 nights per week - Able and willing to provide informed consent (written for biological assessment; verbal for behavioral assessment) Exclusion Criteria: Baseline Assessment: Persons will be excluded from the baseline behavioral assessment if they meet any of the following criteria: - Are not a member of the study community or are not randomly selected to be offered to participate - Are below 18 or above 32 years of age - Has not lived in the community at least 4 months in the past year - Does not sleep regularly in their household at least 2 nights per week - Have an obvious psychological/psychiatric disorder that would invalidate the informed consent process or otherwise contraindicate participation in the assessment Qualitative Cohort: Persons will be excluded from the qualitative cohort if they meet any of the following criteria: - Not a participant in the baseline behavioral assessment - Less than 18 or greater than 32 years of age at enrollment - Have been away from the community for more than two months at a time in the last two years - Demonstrate signs of being visibly distraught, emotionally unstable, or under the influence of psychoactive agents that would invalidate the consent process or otherwise contraindicate participation in the qualitative assessment - Have concrete plans to leave the community, thus removing possibility of follow up Intervention: Persons will be excluded from accessing counseling and testing (CBVCT) through the study (and will be referred to existing alternate services) if they meet any of the following criteria: - <16 years of age - Have an obvious psychological/psychiatric disorder that would invalidate the informed consent process or otherwise contraindicate participation Persons will be excluded from accessing post-test support through the study (and will be referred to existing alternate services) if they meet any of the following criteria: - <16 years of age - Have an obvious psychological/psychiatric disorder that would invalidate the informed consent process or otherwise contraindicate participation Control: - <16 years of age - Have an obvious psychological/psychiatric disorder that would invalidate the informed consent process or otherwise contraindicate participation Post-Intervention Assessment: Persons will be excluded from the post-intervention assessment if they meet any of the following criteria: - Are not a member of the study community or are not randomly selected to be offered to participate - Are below 18 or above 32 years of age - Has not lived in the community at least 4 months in the past year - Does not sleep regularly in their household at least 2 nights per week - Have an obvious psychological/psychiatric disorder that would invalidate the informed consent process or otherwise contraindicate participation in the assessment |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| South Africa | Human Sciences Research Council | Pietermaritzburg | KwaZulu-Natal |
| South Africa | University of the Witwatersrand | Soweto, Johannesburg | Gauteng |
| Tanzania | Muhimbili University | Dar es Salaam | |
| Thailand | Chiang Mai University | Chiang Mai | |
| Zimbabwe | University of Zimbabwe | Harare |
| Lead Sponsor | Collaborator |
|---|---|
| University of California, Los Angeles | HIV Prevention Trials Network, National Institute of Mental Health (NIMH) |
South Africa, Tanzania, Thailand, Zimbabwe,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Prevalence of recent HIV infection | Measured at Year 3 | No | |
| Secondary | Less HIV risk behavior | Measured at Year 3 | Yes | |
| Secondary | Higher rates of HIV testing | Measured at Year 3 | No | |
| Secondary | More favorable social norms regarding HIV testing | Measured at Year 3 | Yes | |
| Secondary | More frequent discussions about HIV | Measured at Year 3 | No | |
| Secondary | More frequent disclosure of HIV status | Measured at Year 3 | No | |
| Secondary | Less HIV-related stigma | Measured at Year 3 | Yes | |
| Secondary | Fewer HIV-related life events | Measured at Year 3 | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |